Milestone Pharmaceuticals (MIST) Q4 2025: Cardamist Launch Drives $200M Cash Position, Sets Up Commercial Ramp
Milestone Pharmaceuticals’ FDA approval and rapid launch of Cardamist marks a watershed for the company, with early prescription traction and a fortified $200 million cash position. The commercial team is executing on broad access and prescriber engagement, but payer coverage and script pull-through remain the gating factors for near-term adoption. Investors should watch the pace of coverage wins and real-world utilization as the launch matures into the back half of 2026.
Summary
- First-in-Class Launch Momentum: Cardamist’s US debut is reshaping acute PSVT treatment dynamics.
- Commercial Execution Focus: Early prescriber engagement is strong, but payer coverage is the key hurdle.
- Balance Sheet Strength: $200 million in pro forma cash underpins launch runway through late 2027.
Performance Analysis
Milestone Pharmaceuticals (MIST) delivered its first revenue from Cardamist, a trypamil nasal spray for paroxysmal supraventricular tachycardia (PSVT), following FDA approval in December 2025. This approval transitioned the company from a clinical-stage biotech to a commercial-stage specialty pharma, with $1.5 million in milestone revenue reflecting the Cork Cell collaboration milestone. R&D and commercial expenses increased sharply year-over-year as the company ramped up launch activities, with commercial spend more than doubling to $28.3 million in 2025, underscoring the investment required to establish Cardamist as a new standard of care.
Net loss widened to $63.1 million as launch-related investments outpaced early revenue, but the company’s cash position was significantly strengthened by the $75 million RTW royalty sale and additional capital raises, resulting in a pro forma cash reserve of $200 million. This capital base affords Milestone a multi-year window to drive Cardamist adoption and pursue international expansion, with the EMA review expected in the first half of 2027.
- Launch-Driven Expense Surge: Commercial and G&A costs rose as the company built out sales and support infrastructure.
- Script Fulfillment Lag: Over 150 prescriptions filled by 100+ unique prescribers, but payer controls are delaying broader pull-through.
- Cash Runway Extension: Pro forma cash of $200 million supports launch and operational runway into late 2027.
Early launch metrics validate operational readiness, but script conversion and payer access will determine the pace of revenue build in 2026. The company’s focus on high-prescribing cardiologists and electrophysiologists positions it well for early adoption among key influencers.
Executive Commentary
"December 2025 marked a transformational event for Milestone Pharmaceuticals with the FDA approval of Cardamist, a trypamil nasal spray for paroxysmal supraventricular tachycardia... Our commercial strategy this year is focused on driving new patient starts and achieving commercial coverage, which, if successful, is expected to accelerate prescription growth."
Joseph Oliveto, President and Chief Executive Officer
"Taking these additional funds into account gives us a pro forma cash number of approximately $200 million. We believe this supports a successful launch of Cardemist and provides us with expected operating runway into late 2027."
Amit Hazija, Chief Financial Officer and EVP of Corporate Development
Strategic Positioning
1. First-Mover Advantage in Acute PSVT
Cardamist is the first FDA-approved, self-administered therapy for acute PSVT in over 30 years, giving Milestone a clear first-mover edge in a market of more than 2 million US patients. The product’s intranasal, rapid-acting profile addresses a significant unmet need for out-of-hospital treatment, potentially reducing emergency department utilization.
2. Commercial Launch Execution and Market Access
The company deployed a 60-person sales force targeting approximately 10,000 providers who manage half of all treated PSVT patients. Early commercial focus is on high-prescribing cardiologists, electrophysiologists, and advanced practice providers (APPs), with over 1,000 weekly engagements and >150 prescriptions filled in the first month. However, payer coverage remains the gating factor for broad uptake, with most prescriptions requiring prior authorization or medical exception.
3. Payer Strategy and Reimbursement Architecture
Milestone’s launch is supported by a robust patient assistance platform, including copay support and reimbursement navigation, to facilitate early script fulfillment. The company is prioritizing commercial payer contracts in 2026, with Medicare access targeted for 2027, and expects initial coverage to include quantity limits and standard prior authorization requirements. The goal is to demonstrate demand and value to payers to secure favorable formulary positioning without excessive rebate pressure.
4. International Expansion Pathway
The EMA accepted the marketing authorization application for Cardamist (Tachymist in Europe) in January 2026, with a decision expected in the first half of 2027. FDA approval serves as a regulatory benchmark, potentially expediting ex-US opportunities and partnerships.
5. Organizational Scale-Up and Compliance
Milestone enhanced its leadership with a new General Counsel and Chief Compliance Officer, reflecting the shift to commercial operations and the need for scalable, compliant infrastructure as the franchise grows.
Key Considerations
Milestone’s launch year is a pivotal test of its ability to convert clinical innovation into durable commercial value, with execution risk concentrated around payer access, script pull-through, and prescriber adoption. The company’s cash position buys time, but not inevitability, as market access and real-world utilization will dictate the revenue ramp and long-term franchise value.
Key Considerations:
- Payer Coverage Bottleneck: Most prescriptions are delayed by prior authorization and insurer review, with more than half of scripts not filled industry-wide in this phase.
- Prescriber Breadth and Early Adoption: Engagement spans cardiologists, electrophysiologists, and APPs, but durable trends will emerge only as coverage expands.
- Patient Mix and Utilization: Roughly 50-50 commercial and Medicare split; product is being prescribed both as a replacement for “pill-in-pocket” and for newly diagnosed patients.
- Real-World Feedback: Early patient sentiment is positive, particularly around peace of mind, but meaningful outcomes data will require more time and volume.
- International Upside: EMA review and potential ex-US partnerships could broaden the addressable market in 2027 and beyond.
Risks
Commercial execution risk is high given dependence on payer coverage and script pull-through, with industry benchmarks suggesting significant early attrition. Reimbursement delays, rebate pressure, and restrictive quantity limits could dampen near-term adoption. Regulatory timelines and ex-US approvals add uncertainty, while the need to scale compliance and manufacturing infrastructure introduces operational complexity. Management’s guidance is appropriately cautious given the nascency of the launch and limited real-world data.
Forward Outlook
For Q1 2026 and the remainder of the year, Milestone expects:
- Continued ramp in Cardamist prescriptions and unique prescribers as commercial efforts intensify.
- Expansion of payer coverage, with commercial contracts targeted in 2026 and Medicare in 2027.
For full-year 2026, management did not provide explicit revenue guidance but reiterated:
- Focus on demonstrating real-world demand to accelerate coverage discussions.
- Operating runway into late 2027, supported by $200 million in pro forma cash.
Management highlighted that meaningful launch progress is expected in the back half of 2026 as coverage expands and script fulfillment accelerates.
- Watch for updates on contracted coverage and script conversion rates.
- Monitor patient and prescriber feedback as real-world data emerges.
Takeaways
Milestone’s transition to commercial-stage execution is underway, with Cardamist’s launch targeting a significant unmet need in acute PSVT. The company’s financial strength and operational readiness are clear, but near-term growth will be dictated by payer access and script pull-through trends over the next 12 months.
- Launch Foundation: Cardamist is available nationwide with a trained sales force and initial prescriber uptake, but payer friction is limiting early fill rates.
- Strategic Patience Required: Management is realistic about the early bottlenecks and is focused on building demand to strengthen its negotiating position with payers.
- Investors Should Track: Quarterly updates on contracted coverage, unique prescribers, and script pull-through will be the key signals of launch trajectory and long-term franchise potential.
Conclusion
Milestone Pharmaceuticals enters 2026 with a landmark product launch, strong cash reserves, and a clear focus on payer access and real-world adoption. The next phase will test the company’s ability to convert clinical innovation into commercial momentum as Cardamist’s value proposition is proven in the marketplace.
Industry Read-Through
Milestone’s Cardamist launch underscores the challenges and opportunities for first-in-class specialty pharma products in acute care markets, particularly where payer coverage and prescriber education are critical to uptake. The company’s emphasis on patient support, rapid sales force deployment, and payer engagement offers a playbook for other specialty launches targeting entrenched acute care pathways. For cardiovascular drug developers, the pace of payer adoption and the role of advanced practice providers in script initiation will be key industry watchpoints in 2026. Investors should monitor how quickly new therapies can shift treatment paradigms in historically static markets, and how commercial-stage biotechs manage the balance between aggressive launch investment and disciplined cash burn.